Based on these previous reports showing the therapeutic advantages of an EPO and G-CSF combination [30,33], we evaluated whether EPO+G-CSF combination therapy safely yielded hematological and functional improvement in stroke patients. This evidence concerns the gene CSF3 and stroke disorder.